C ardiovascular mortality remains the leading cause of death in patients with chronic kidney disease (CKD). 1 The extent of arterial calcification independently predicts cardiovascular disease and mortality in patients with CKD, 2 and this ectopic calcification occurs decades earlier in patients with CKD than in the general population. 3 The calcium phosphate mineral deposits occur in the form of hydroxyapatite or whitlockite 4 and can contribute to disease progression in 2 main locations within arterial vessels: the intimal layer and the medial layer. Calcification associated with the intimal layer is a reflection of atherosclerotic burden and may result in arterial occlusion. Arterial medial calcification (AMC) contributes to vascular stiffening without occlusion and can lead to hypertension and heart failure. Studies have shown that AMC is a dominant form of vascular calcification (VC) in dialysis patients. [4] [5] [6] During the past decade, elevated serum phosphorus has emerged as a key risk factor for VC in patients with CKD, as well as the general population. [7] [8] [9] High extracellular phosphate has been widely established to induce vascular smooth muscle cell (VSMC) matrix calcification in vitro. [10] [11] [12] Indeed, elevated phosphate has been linked to several highly regulated processes in the vessel wall that promote AMC. These include VSMC osteogenic differentiation, VSMC apoptosis, and matrix degradation (reviewed in Lau et al 13 and Shanahan et al
The type II (SLC34 family) cotransporters, predominantly expressed in kidney and intestinal epithelium, are important for whole-body phosphate homeostasis. 17, 18 The type III (SLC20 family) cotransporters, PiT-1 and PiT-2, are more generally expressed 19 and have been identified as the predominant phosphate transporters in rat 20 and human 21 VSMCs. PiT-1 and PiT-2 are 62% identical at the amino acid level and both contain 12 transmembrane spanning domains with a single large intracellular domain. They exhibit a high affinity for phosphate and have a preference to transport H 2 PO 4 − more than HPO 4 2− , with a 2:1 ratio of sodium:phosphate in both acidic and alkaline pH. 19 The Michaelis-Menten affinity constant (K m ) for sodium-dependent phosphate uptake for PiT-1 and PiT-2 is similar and ranges from 25 to 300 μmol/L phosphate depending on the species. 19, 20, [22] [23] [24] We have shown previously that PiT-1 was required for phosphate-induced osteogenic differentiation and calcification of human VSMCs in vitro. 21 When PiT-1 was knocked down in human aortic VSMCs using short hairpin RNA interference (shRNA), phosphate-induced mineralization was suppressed, and VSMC phenotype was preserved. Subsequent overexpression of mouse PiT-1 restored phosphate transport, VSMC osteogenic phenotype change, and calcification. 21 Given the compelling in vitro evidence, we hypothesized that PiT-1 would be required for VC in vivo. To test this, a well-characterized mouse model of phosphate-driven uremic AMC was used. [25] [26] [27] Calcification-prone DBA/2J mice, 28 when subjected to partial renal ablation, develop robust AMC on dietary phosphate loading without atherosclerosis or inflammation. [25] [26] [27] As global deletion of PiT-1 is lethal during mouse embryogenesis, 24, 29 we generated VSMCspecific knockout of PiT-1 using a SM22 promoter-driven Cre/loxP system. This resulting PiT-1 flox/flox ;Sm22-Cre +/0 dual transgenic mouse line (abbreviated as PiT-1 ∆sm ) lacked PiT-1 expression in VSMCs. Unexpectedly, sodium-dependent phosphate uptake and matrix mineralization in isolated VSMCs, as well as high-phosphate feeding-induced uremic AMC, did not differ between PiT-1 ∆sm and PiT-1 flox/flox control mice, prompting us to examine potential compensatory mechanisms. Our data indicate that PiT-2 compensates for PiT-1 in phosphate uptake and matrix mineralization in vitro and are the first to suggest redundant roles for PiT-1 and PiT-2 in phosphate-driven AMC.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PiT-1 and PiT-2 Are the Only NaPi Cotransporters Expressed by Mouse VSMCs
Reverse transcription polymerase chain reaction (PCR) was used to determine the expression profile of NaPi cotransporters in cultured C57/Bl6 wild-type VSMCs. Using this technique, no specific bands were obtained using primers for type I transporters (SLC17A1, A4 and A7) or type II transporters (SLC34A1, A2 and A3), whereas both type III transporters were detected ( Figure I in the online-only Data Supplement).
VSMC-Specific Knockdown of PiT-1
In contrast to the global PiT-1 knockout that resulted in embryonic lethality because of anemia, 24, 29 mice with smooth muscle-specific PiT-1 deletion were born at the expected Mendelian ratios and showed no gross abnormalities in health, weight, or lifespan (data not shown). Likewise, histological analyses of aortas from these mice were normal (data not shown). As shown in Figure II in the online-only Data Supplement, PCR amplification of genomic DNA isolated from VSMCs from PiT-1∆ sm mice showed a 500-bp band (compared with 950 bp band in the PiT-1 flox/flox cells) consistent with deletion of exons 3 and 4. Western blotting confirmed the depletion of PiT-1 protein in whole aortic tissue in PiT-1∆ sm mice ( Figure 1A and 1B), and immunochemistry showed selective PiT-1 depletion in VSMCs but not endothelial cells ( Figure 1C) . Consistent with the immunostaining data, PiT-1 mRNA was undetectable in the aortic media isolated from healthy PiT-1∆ sm mice ( Figure III in the online-only Data Supplement). Because a trend for decreased expression of PiT-1 mRNA in cardiac tissue from PiT-1∆ sm compared with PiT-1 flox/flox was observed, and because SM22α is transiently expressed in the heart during mouse embryogenesis, 30 there was a possibility that SM22α promoter-driven PiT-1 deletion could have affected cardiogenesis. However, resting echocardiography under minimal sedation on healthy PiT-1∆ sm mice showed no difference in ejection fraction, left ventricular wall thickness, and left ventricular end-diastolic volume, compared with wild-type controls (Table II in the online-only Data Supplement).
Deletion of PiT-1 From VSMCs Had No Effect on AMC Induced by Uremia and High-Phosphate Feeding
We previously developed and characterized a CKD mouse model of AMC using calcification-prone DBA/2J mice fed a high-phosphate diet. [25] [26] [27] In this model, robust AMC in the absence of inflammation or atherosclerosis develops in CKD mice in response to high-phosphate feeding but does not occur in CKD mice fed a normal phosphate diet. Thus, this model is well suited to investigating the role of phosphatedependent mechanisms in AMC. To determine whether the sm mice (n=16 per group). After feeding with the highphosphate diet for 4 weeks, calcium accumulated in the aorta as expected, but the extent of calcification did not differ significantly between the 2 groups ( Figure 2A) . Consistent with previous studies, [25] [26] [27] no AMC was observed in CKD mice fed a normal phosphate diet (PiT-1 flox/flox =0.9±0.1 μg/mg; PiT-1∆ sm =0.6±0.1 μg/mg). Serum chemistries after renal ablation were not statistically different between groups fed high phosphate (Table) , suggesting that differences in the degree of renal ablation or hyperphosphatemia achieved did not explain the lack of effect of PiT-1 deletion on AMC. Figure 2C -v and 2C-vi), was apparent in both groups. Furthermore, transcriptional profiling of aortic mRNA showed increased expression of osteochondrogenic markers Runx2, osteopontin, and osteoprotegerin in CKD versus healthy PiT-1 flox/flox mice aortas, but no statistically significant differences were observed in these genes between CKD PiT-1 ∆sm and PiT-1 flox/flox mice fed a high-phosphate diet (Table III in the online-only Data Supplement). Finally, because recent studies have implicated PiT-1 in cell proliferation and survival, 31, 32 we counted the number of VSMCs per cross-sectional area of aorta to determine whether there was a reduction in VSMCs within the medial layer. VSMC cell densities in PiT-1 flox/flox and PiT-1 ∆sm were 3565±378 and 4158±332 cells/mm 2 (mean±SEM), respectively, showing no statistical difference between genotypes (P=0.27).
Aortas From
SMC-Specific Deletion of PiT-1 Did Not Alter Phosphate-Induced Calcification of Aortic Rings and Cultured VSMCs
To determine whether compensatory circulating factors might explain the lack of effect of PiT-1 deletion on AMC in uremic mice, in vitro calcification of aortic rings and isolated VSMCs was assessed. Aortas were harvested from PiT-1 flox/flox and PiT-1∆ sm mice to generate aortic rings, and calcification was induced by incubation in high-phosphate media for 9 days. As shown in Figure 3A , there was no significant difference in calcification between the 2 groups. Similar to the results in aortic rings, we found no significant difference in the extent of calcification between PiT-1∆ sm and PiT-1 flox/flox in cultured VSMCs after treatment with high-phosphate media for 6 to 10 days ( Figure 3B ).
Deletion of PiT-1 in Mouse VSMCs Had No Effect on Phosphate Uptake
Sodium-dependent phosphate uptake kinetics were determined in cultured VSMCs from PiT-1 flox/flox and PiT-1 ∆sm mice and revealed no significant differences between the 2 genotypes when nonlinear curve fitting assuming MichaelisMenten kinetics was performed (P=0.6; Figure 3C ). The V max was measured as 0.315±0.042 and 0.285±0.038 pmol/μg protein per minute with a K m of 0.223±0.061 and 0.205±0.057 mmol/L for the PiT-1 flox/flox and PiT-1 ∆sm VSMCs, respectively. Sodium-dependent uptake was unchanged in the presence of 0 to 1 mmol/L phosphonoformic acid, an inhibitor of type II NaPi transport ( Figure 3D ). As the K i of phosphonoformic acid for PiT-1 and PiT-2 is in the range of 2.5 to 5 mmol/L, 33, 34 lack of inhibition by phosphonoformic acid at submillimolar concentrations indicated that type II transporters were not contributing to phosphate uptake in the cultured VSMCs. This finding is consistent with the reverse transcription PCR data that showed no expression of type II transporters in mouse VSMCs ( Figure I in the online-only Data Supplement).
VSMC-Specific Knockdown of PiT-1 Was Associated With PiT-2 Upregulation
Because sodium-dependent phosphate uptake was unchanged in PiT-1 knockout cells compared with controls, we suspected that PiT-2 might be compensating for the loss of PiT-1 in VSMC. Real-time quantitative PCR showed that aortic media PiT-2 mRNA was 2-fold higher in PiT-1∆ sm mice compared with PiT-1 flox/flox controls. All other tissues examined showed no difference in PiT-2 expression between the genotypes ( Figure 4A ). Likewise, aortic VSMCs isolated from and PiT-1∆ sm mice had 2-fold higher PiT-2 mRNA levels compared with PiT-1 flox/flox (P<0.002; Figure 4B ). Consistent with the mRNA data, PiT-2 protein levels were increased ≈1.6-fold in whole aorta extracts and ≈3.8-fold in VSMC extracts from PiT-1∆ sm mice compared with PiT-1 flox/flox ( Figure 4C and 4D). Expression of type I (SLC17a1) and type II (SLC34a1, SLC34a2, or SLC34a3) sodium-dependent phosphate cotransporters was undetectable in the aortas of high-phosphate-fed PiT-1 flox/flox and PiT-1∆ sm CKD mice (data not shown).
Overexpression of PiT-2 in PiT-1 Knockdown VSMCs Restored Phosphate Uptake and Phosphate-Induced Calcification
We previously reported that knockdown of PiT-1 expression in human VSMCs using shRNA decreased phosphate uptake, phosphate-induced calcification, and osteogenic differentiation without compensation by PiT-2. 21 Thus, to determine whether PiT-2 could functionally compensate for the loss of PiT-1 in VSMCs, we overexpressed PiT-2 by retroviral transduction into PiT-1 knockdown human VSMCs that were previously shown to express ≈80% less PiT-1 than controls. 21 Overexpression of PiT-2 was confirmed by quantitative PCR (Figure 5A , graph) and Western blotting ( Figure 5A , BUN was measured in all mice. Pre-CKD Ca and P were measured from 6 mice per group, CKD Ca and P were measured in 3 mice per group. Data are mean±SE. Parameters were not significantly different between groups. BUN indicates blood urea nitrogen; Ca, calcium; n, number of mice in each treatment group; and P, phosphate. inset). Overexpression of PiT-2 restored phosphate uptake ( Figure 5B ) and calcification ( Figure 5C ) in PiT-1 shRNA cells. Overexpression of PiT-2 also significantly promoted osteogenic differentiation of VSMCs as measured by a 30% increase in osteogenic index (ratio of osteopontin/SM22α mRNA levels) compared with vector control after elevated phosphate treatment (data not shown). These data indicated that PiT-2 could functionally compensate for the loss of PiT-1 in terms of phosphate uptake, phosphate-induced osteogenic differentiation, and calcification.
Knockdown of PiT-2 in PiT-1-Deficient Mouse VSMCs Decreased Phosphate Transport and Phosphate-Induced Calcification
To determine whether PiT-2 was functionally compensating for PiT-1 in the PiT-1∆ sm VSMCs, we transduced these cells with scrambled control or PiT-2-specific shRNA to create PiT-1/PiT-2 double knockdown VSMCs. In these cells, PiT-2 mRNA expression was reduced by ≈80% compared with the control cells ( Figure 6A ). Subsequently, sodiumdependent phosphate uptake was significantly decreased by ≈35% ( Figure 6B ) and phosphate-induced calcification was significantly decreased by ≈20% in PiT-1 knockdown VSMCs compared with the scrambled control ( Figure 6C ).
Discussion
Overall, our studies show that deletion of PiT-1 selectively from VSMCs does not alter the extent of AMC in CKD mice fed a high-phosphate diet. Similarly, sodium-dependent phosphate uptake in VSMCs, as well as calcification of explanted aortic rings, and VSMC primary cultures treated with highphosphate media were equivalent in PiT-1 ∆sm and PiT-1 flox/flox mice. Interestingly, PiT-2 expression was increased 2-fold in PiT-1 ∆sm VSMCs compared with PiT-1 flox/flox mice, suggesting that this type III NaPi family member might be compensating for the loss of PiT-1. A compensatory role was supported by in vitro studies because overexpression of PiT-2 restored calcification in cultured PiT-1-deficient human VSMCs; in addition, knockdown of PiT-2 in PiT-1 ∆sm VSMCs diminished calcification. These are the first studies to demonstrate a redundant role for PiT-1 and PiT-2 in VC.
Previous work in our group demonstrated a role for PiT-1 in phosphate-induced human VSMC calcification and osteochondrogenic transformation in vitro. 21 Knockdown of PiT-1 by shRNA suppressed phosphate-induced calcification and osteochondrogenic phenotype change but did not block SMC apoptosis induced by high phosphate under serum-free conditions. Others have seen similar results in osteoblast cultures where knockdown of PiT-1 reduced matrix mineralization and reduced expression of osteoblast markers such as osteopontin. 35, 36 More recently, Sugita et al 37 found that cellular phosphate transport and ATP synthesis mediated by PiT-1 were critical for chondrogenesis in mice. Together, these studies support the hypothesis that PiT-1 is a key player in elevated phosphate-induced calcification. Thus, it was surprising that no differences in SMC phenotype modulation or AMC were observed between PiT-1 ∆sm and PiT-1 flox/flox mice after CKD and high-phosphate feeding. Furthermore, no difference was observed in calcification of cultured aortic rings from PiT-1 ∆sm and PiT-1 flox/flox mice, suggesting that compensation by circulating factors was unlikely. Finally, isolated VSMC from PiT-1 ∆sm and PiT-1 flox/flox showed no difference in sodium-dependent phosphate uptake kinetics in vitro. These findings led us to consider a potential cell autonomous compensatory mechanism in SMCs deficient in PiT-1.
We discovered that PiT-2 mRNA expression was upregulated in aortas in response to developmental loss of PiT-1 specifically in mouse SMCs. This finding was distinct from our previous findings in human VSMC, where levels of PiT-2 were low and unchanged after shRNA knockdown of PiT-1, pointing to a potential developmental compensatory mechanism (discussed in more detail below). The increase in PiT-2 expression in PiT-1 ∆sm aortas was selective because no change in other known sodium-dependent phosphate cotransporters was detected. The increase in PiT-2 compensated for PiT-1 in phosphate transport and VC in vitro. Overexpression of PiT-2 in PiT-1-deficient human SMC restored phosphate uptake and calcification after elevated phosphate treatment. Furthermore, siRNA knockdown of PiT-2 in PiT-1 ∆sm VSMCs diminished both phosphate uptake and calcification. Together, these data support the hypothesis that PiT-2 could compensate for PiT-1 in both sodium-dependent phosphate uptake and phosphate-induced calcification.
Although we were able to knockdown PiT-2 mRNA levels by ≈80% in PiT-1 ∆sm VSMC, we observed only a 35% decrease in sodium-dependent phosphate uptake and 20% decrease in phosphate-induced calcification. There are several possible explanations for this observation. First, a low density of PiT-2 transporter may be sufficient, within the duress of a high-phosphate milieu, to initiate the signaling cascade that results in VSMC calcification. Second, because decline in phosphate uptake and phosphate-induced calcification were comparable, our data might suggest that the phosphate uptake function of PiT-2 is most critical for VSMC calcification. Finally, a combination of these mechanisms may be acting to explain the results.
A review of the literature shows that regulation of PiT-1 and PiT-2 expression is specific to the cell type, physiological state, and treatment agent. Byskov 32 (in MC3T3-E1 and NIH3T3 cell lines) and our laboratory (unpublished data in mouse VSMCs) have shown that the expression of PiT-1 and PiT-2 is variable based on cell density in vitro, whereby increased cell density results in lower PiT-1 and PiT-2 mRNA expression. Bone morphogenetic protein-2 has been shown to increase PiT-1, but not PiT-2, mRNA expression in MC3T3-E1 osteoblast cell and human VSMC in vitro. 35, 38 Likewise, platelet-derived growth factor-BB increased PiT-1 mRNA and protein in rat VSMCs with no change in PiT-2. 39 Our data showing PiT-2 upregulation in VSMCs in response to PiT-1 deletion are in agreement with other reports. Beck et al 24 demonstrated that in mice with a global deletion of PiT-1, PiT-2 was upregulated in the embryonic liver, and Byskov et al 32 showed PiT-2 mRNA upregulation in MC3T3-E1 after PiT-1 shRNA knockdown. However, we are the first to demonstrate that PiT-2 can functionally compensate for PiT-1 in VSMC calcification.
As mentioned above, PiT-2 mRNA expression was upregulated in VSMCs in response to developmental loss of PiT-1 specifically in mouse SMCs, and this finding was in contrast to results obtained when shRNA was used to more acutely knockdown PiT-1 in cultured human SMCs. Although the underlying mechanisms of developmental compensation are often enigmatic, the increased level of PiT-2 expression observed in the PiT-1 knockout mice, together with published literature, suggests ≥2 potential compensatory mechanisms. In the first hypothetical mechanism, a decrease in PiT-1 triggers a regulatory switch, which in turn results in increased transcriptional activation of PiT-2, either through increased expression or post-translational stabilization of a transcriptional activator, or increased accessibility of the PiT-2 promoter. Molecular cloning and sequence analysis have revealed several potential cis-acting elements in the PiT-2 promoter, including a CACCC (Kruppel-like factor) binding site, thyroid hormone response elements, serum response elements, retinoic acid response elements, and vitamin D3-response elements. 40 Examination of the endogenous activity of these candidate upstream regulators and their interaction with the PiT-2 promoter in vivo may reveal important information about the mechanism of compensation. Importantly, a KLF family member was recently shown to regulate expression of PiT-1 during erythroid maturation. 41 Alternately, the compensatory mechanism may be independent of transcriptional regulation. A decrease in phosphate levels is known to result in enhanced mRNA stability of PiT-2. 42, 43 It is possible that the decrease in phosphate intake caused by the absence of PiT-1 during development results in a prolonged half-life of PiT-2 and, in turn, the higher levels of PiT-2 mRNA that we observed by quantitative PCR ( Figure 4A ). Future analysis of PiT-1/PiT-2 double knockout models along with evaluation of candidate PiT-2 transcriptional regulators and examination of PiT-2 mRNA stability in vivo will be required to test these 2 hypotheses. Finally, potential species differences in PiT compensation cannot be ruled out.
The idea that both PiT-1 and PiT-2 may be important regulators of VC is further strengthened by recent findings in rare human genetic syndromes. Wider et al 44 found that mutations in PiT-2 associated with impaired phosphate transport caused familial idiopathic basal ganglia calcification, a condition characterized by mineralization of capillaries, as well as small arteries and veins of the basal ganglion region. 44 Although the exact mechanism for this effect is unknown, the authors speculated that the loss of PiT-2 function and regional phosphate homeostasis might lead to increased PiT-1 function in VSMC, thereby promoting osteochondrogenic differentiation and calcification. Furthermore, the overexpression of PiT-1 has been reported in fibroblasts derived from patients with Werner syndrome, an autosomal recessive disorder caused by mutations in RecQ DNA helicase that is characterized by premature aging and soft tissue calcification. 45 In summary, although we have shown that the extent of AMC in high-phosphate-fed uremic mice was not different either between the PiT-1∆ sm and PiT-1 flox/flox or in vitro using VSMC primary culture from these mice, we discovered increased PiT-2 expression in the PiT-1∆
sm VSMCs. Using in vitro methods, we demonstrated that PiT-2 overexpression could compensate for phosphate uptake and phosphateinduced calcification in PiT-1-deficient VSMCs, whereas knockdown of PiT-2 reduced phosphate uptake and calcification. Taken together our data suggest redundant roles for PiT-1 and PiT-2 in phosphate-driven AMC. 
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Vascular calcification (VC) is a major risk factor for cardiovascular morbidity and mortality, and elevated phosphate has been identified as a key inducer of vascular calcification via procalcific effects on vascular smooth muscle cells. We identified a novel function for the sodiumdependent phosphate transporter, PiT-2, as a mediator of elevated-phosphate-induced vascular calcification in vitro and in vivo. Moreover, we provide mechanistic insight into compensatory mechanisms that operate in smooth muscle cells to protect against phosphate transporter deficiency. Importantly, as our studies were in progress, PiT-2 was identified as the causative gene for idiopathic basal ganglion calcification in people, and thus our studies noting compensatory mechanisms for phosphate transporters may help to explain how mutation of PiT-2 might lead to compensatory changes that actually facilitate vascular calcification. Clinically, our data provide a cautionary note on compensatory pathways that should be considered when attempting to translate inhibition of phosphate transport to clinical therapies.
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